Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- ALS Association invests $3M to bring access to care closer to home
- Protein recycling system may be treatment target in ALS
- New AI matchmaker pairs ALS patients with clinical trials in seconds
- How my husband and I try to teach our children well in life with ALS
- ALS treatment tazbentetol gets FDA fast track status